Navigation Links
Evonik Extends Long-term Research & Development Partnership with Genedata
Date:2/23/2010

Significant Expansion of Genedata Phylosopher® and Genedata Expressionist® at Evonik for Industrial Biotechnology R&D Processes

Basel, Switzerland (PRWEB) February 23, 2010 -- Genedata, a leading provider of advanced software solutions for industrial biotechnology R&D, today announced an extended partnership with Evonik, a leading life science, specialty chemicals and material science company. Evonik is expanding the application of its central computational infrastructure and has renewed licenses for the Genedata Phylosopher® research data management system and the Genedata Expressionist® cross-omics and molecular profiling system. Genedata systems are now used across biotechnology research and development processes in the fields of health and nutrition and consumer specialties at Evonik. Specific applications areas include: production strain optimization for feed, food and pharma amino acids and derivatives; process monitoring for fermentation-based production; and novel developments for care specialties.

Genedata’s software is key for us to efficiently store, process and interpret the biological and bioprocess-related data generated at our R&D and global production sites,” said Stephan Hans, head of Functional Cell Analysis Group, R&D Bioproducts at Evonik. “With Genedata’s data management solutions we are able to centrally manage all data related to our proprietary production strains and processes. Data integrity, accessibility and process support are the main reasons why Evonik decided to use Genedata systems in the first place, and why Evonik is now broadening their application spectrum.”

Transcriptomics and metabolomics have become essential technologies for guiding our strain development processes. The increasing data complexity and data volumes acquired in each strain and process development project is dramatic, which is why we need a stable and scalable computational solution,” noted Dr. Ralf Kelle, vice president of R&D Biotechnology at Evonik. “In addition, strain genotyping using next-generation sequencing technology has enabled us to systematically assess whole strain ancestries on a molecular level. Genedata’s tools pinpoint production-relevant mutations and evaluate their impact on genes, pathways and overall production phenotypes.”

"We are proud to have been able to broaden our relationship with Evonik, a major player in industrial biotechnology,” commented Dr. Othmar Pfannes, CEO of Genedata. “Our computational platform is tailored to support biotechnological research and development processes. The increasing demand for bio-based products and sustainable production processes is driving our continuous commitment to develop solutions for the white biotech market.”

About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery and life science research, which spans target, lead and biomarker discovery. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata Phylosopher®, Genedata Screener®, and Genedata Expressionist® make research data accessible and understandable, enabling scientific discovery that fights disease and improves health worldwide. Founded in 1997, Genedata is privately held, with headquarters in Basel, Switzerland, and offices in Japan, Germany and the US. www.genedata.com

Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

# # #

Read the full story at http://www.prweb.com/releases/strain_development/industrial_biotech/prweb3625804.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related biology technology :

1. Dyadic International Extends Collaboration With The Scripps Research Institute
2. Jellyfish Protein Extends Neuroprotective Tentacles at Neuroscience Conference
3. NASA Extends Bioastronautics Contract With Wyle for Total Value of $976 Million
4. GeneThera Extends its Reach Overseas
5. Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule
6. Endo Pharmaceuticals Extends Subsequent Offering Period for Indevus Shares Until 5:00 pm EDT on Wednesday, March 18, 2009
7. BVF Acquisition LLC Extends Avigen Tender Offer to April 3, 2009
8. BVF Acquisition LLC Extends Avigen Tender Offer to March 6, 2009
9. BioMed Realty Trust Extends Leases With Vertex Pharmaceuticals Through 2015
10. GlaxoSmithKline Reduces Minimum Tender Condition and Extends Tender Offer To Acquire Genelabs Technologies, Inc.
11. GlaxoSmithKline Extends Tender Offer for Genelabs Technologies, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... Feb. 16, 2017 UCHealth ( Aurora, ... LungDirect for pulmonary nodule patient management. In addition to ... a spot on the lung, UCHealth looks to improve ... data entry. Stephanie Brown, RN , ... nodule patients with an Excel spreadsheet, which was extremely ...
(Date:2/16/2017)... HACKENSACK, N.J. , Feb. 16, 2017  Champions ... engaged in the development and sale of advanced technology ... of oncology drugs, today announced the addition of new ... These new models will expand Champions, product ... cancer, head and neck cancer, AML, and non-small cell ...
(Date:2/16/2017)... Feb. 16, 2017  Windtree Therapeutics, Inc. (Nasdaq: ... on developing aerosolized KL4 surfactant therapies for respiratory ... influenza study showed that aerosolized KL4 surfactant reduced ... well-established preclinical animal model. The Company believes that ... of evidence that supports the role of KL4 ...
(Date:2/16/2017)... PHOENIX and NEW YORK ... announced the near completion of their $7M Series B ... on top of the $3.5M led by Mesa Verde ... of 2016.  These resources will be directed towards further ... Test, PCDx, a comprehensive genomic profiling test and expanding ...
Breaking Biology Technology:
(Date:2/10/2017)... , Feb 10, 2017 Research ... report "Personalized Medicine - Scientific and Commercial Aspects" ... ... medicine. Diagnosis is integrated with therapy for selection of treatment ... early detection and prevention of disease in modern medicine. Biochip/microarray ...
(Date:2/8/2017)... Feb. 7, 2017  Aware, Inc. (NASDAQ: AWRE ... reported financial results for its quarter and year ended December ... of 2016 was $3.9 million compared to $6.9 million in ... quarter of 2016 was $0.6 million compared to $2.6 million ... fourth quarter of 2016 was $0.5 million, or $0.02 per ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... billion by 2021 from $8.3 billion in 2016 at ... 2016 to 2021. Report Includes - An overview ... global market trends, with data from 2015 and 2016, ... 2021. - Segmentation of the market on the basis ...
Breaking Biology News(10 mins):